Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension
Abstract
Aim: Selexipag has demonstrated safety and efficacy in the treatment of pulmonary arterial hypertension (PAH). However, the strategy of triple therapy involving selexipag and its impact on right heart remodeling requires further clarification in Chinese patients with PAH.
Methods and results: This investigation was conducted as a single-center, retrospective study. Patients with PAH who presented to Qilu Hospital of Shandong University from February 2022 to November 2023 with a definitive diagnosis of Group 1 PAH and who received a triple targeted therapy based on selexipag were included for a safety and efficacy evaluation. Data for the French pulmonary hypertension network non-invasive risk assessment, echocardiogram parameters, and clinical data were collected. Comparisons between initial and early sequential triple combination were conducted. A total of 153 patients were entered into the safety analysis and 146 patients were included in the efficacy analysis. No unknown side effects were reported. After selexipag treatment for 29 weeks in median, 96 (65.8%) reached WHO FC II compared to 39 (26.7%) at baseline (p p p p = 0.036, 95% CI: 0.035-0.898) for initial triple combination therapy, compared to early sequential selexipag add-on therapy.
Conclusion: Triple-targeted drug therapy containing selexipag can be safely and effectively used in Chinese PAH patients, significantly enhancing exercise capacity, improving right heart structure and function, and optimizing risk…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 153 participants or records.
Read the paper
Related studies
- Protective effects of tadalafil and N-acetyl cysteine therapy on cisplatin-induced testicular toxicity
- The Use of Generative AI for Scientific Literature Searches for Systematic Reviews: ChatGPT and Microsoft Bing AI Performance Evaluation
- Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons
- Ozone-modified properties of pumpkin seed oil as anti-H. pylori, anticancer, anti-diabetic and anti-obesity agent
- Effectiveness of Low-Intensity Extracorporeal Shock Wave Therapy in Erectile Dysfunction: An Analysis of Sexual Function and Penile Hardness at Erection: An Umbrella Review
- Molecular Docking of Silymarin as a Ligand for Aromatase Enzyme and HIV-1 Reverse Transcriptase Using Molegro Virtual Docker
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.